TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03000920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS before invitation
Description: A couple of days before the invitation letter, an SMS will be sent to announce the arrival of the invitation letter to the mammogram

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS before invitation
Description: A couple of days before the invitation letter, an SMS will be sent to announce the arrival of the invitation letter to the mammogram

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS Reminder 1
Description: If it is necessary for the women to have a reminder 1, the usual mail will be replaced by an SMS.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS Reminder 1
Description: If it is necessary for the women to have a reminder 1, the usual mail will be replaced by an SMS.
Study: NCT00461552

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leptin
Description: weight based, sub-cutaneous injection, twice daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: weight based, sub-cutaneous injection, twice daily
Study: NCT03811782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single-task Training
Description: In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Single-task Training instructions (20 minutes) and cool down (5 minutes).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-task Training
Description: In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Dual-task Training instructions (20 minutes) and cool down (5 minutes).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Analogy Training
Description: In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Analogy Training instructions (20 minutes) and cool down (5 minutes).
Study: NCT03284931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217 high dose
Description: high dose
Study: NCT02756494

Intervention type: BIOLOGICAL
Intervention: Ischemic Stroke
Description: Ischemic Stroke in Chinese Young Adults
Study: NCT03284931

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217 low dose
Description: low dose
Study: NCT01593566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% Bupivacaine
Description: Femoral nerve block using 0.25% versus 0.5% bupivacaine
Study: NCT01277523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium low dose
Description: 2 actuations once daily
Study: NCT01593566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% Bupivacaine
Description: Femoral nerve block using 0.25% versus 0.5% bupivacaine for analgesia after ACL reconstruction
Study: NCT00086060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise regimen
Description: Aerobic Exercise is a self-management technique that increases personal control over pain by enhancing physical fitness. Patients will be encouraged to choose activities best suited to their tastes and current lifestyle, incorporating lifestyle physical activities (climbing stairs, household chores, etc) and more traditional exercise activities (walking, cycling, etc.). Subjects will use ratings of perceived exertion (RPE) to guide their effort. The intervention will consist of two-hours of face-to-face contact followed by weekly telephone contact for 8 weeks. Face-to-face contract will include receiving a standardized instruction manual for exercise, a demonstration on how to perform relaxation, and tailoring homework assignments to be monitored on the weekly phone call.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation training
Description: Relaxation is a self-management technique that increases personal control over pain by relaxing tense muscles, allowing the body to rest, and improving mental clarity through concentration and attention and has a great deal of empirical research supporting its effectiveness as a means of pain management. A variety of relaxation skills will be taught with some being based on muscle relaxation, and others focused more on cognitive relaxation and imagery. The intervention will consist of two-hours of face-to-face contact followed by weekly telephone contact for 8 weeks. Face-to-face contract will include receiving a standardized instruction manual for relaxation, a demonstration on how to perform relaxation, and tailoring homework assignments to be monitored on the weekly phone call.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Participants in the standard care control group will not receive any additional intervention beyond that which they are receiving from their routine health care professional.
Study: NCT01979029

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preserving the left colic artery
Description: The root of the inferior mesenteric artery(IMA) was carefully dissected and the artery wall was exposed all the way to the bifurcation of the left colic artery(LCA) and the superior rectal artery (SRA), exposing the LCA from its root until the inferior mesenteric vein (IMV) was recognized. Subsequently, dissection was continued along the IMV up to the level of the root of the IMA. Then the sigmoid mesentery was transected from the root of the IMA to the IMV, and the IMV and the root of the SRA were ligated. Finally, the adipose tissue with the lymph nodes in the area surrounded by the IMA, IMV, and LCA was dissected, with preservation of the LCA .
Study: NCT04079153

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular advancement Appliance
Description: Advances the mandible at desired range at a fixed vertical dimension
Study: NCT03700437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting-Mimicking Diet
Description: Chemo-immunotherapy + FMD (fast-mimicking diet)
Study: NCT02110797

Intervention type: OTHER
Group type: OTHER
Intervention: biological markers and evaluation of the mineral density at the lumber spine using DEXA
Study: NCT03371901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy with BFR-LLST
Description: The criteria-based rehabilitation protocol for the patients with cartilage or meniscus repair may vary according to the surgical procedures.~Patients will attend 5 individual treatments, and a 6-week supervised group-based rehabilitation program with BFR-LLST (Blood Flow Restriction - Low Load Strength Training) twice a week at the rehabilitation centre. Patient will be instructed to perform BFR-LLST 5 times a week in total (twice supervised, 3 times at home).~During each BFR-LLST session, patients are encouraged to perform 4 sets of 30 repetitions, 15 repetitions, 15 repetitions, and 15 repetitions (or to fatigue in the final set), respectively.~The exercise intervention will adhere to TIDieR (template for intervention description and replication).
Study: NCT03445819

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Group A: Surgical Treatment
Description: Open reduction and internal fixation (ORIF) of the patellar fracture will be performed using screws, wires, pins, or plate fixation at the discretion of the treating surgeon

Intervention type: OTHER
Group type: OTHER
Intervention: Group B: Conservative Treatment
Description: Patients randomized to non-operative treatment will receive identical treatment to the operative group, minus the surgery.
Study: NCT03561623

Intervention type: OTHER
Intervention: magnetic resonance (MR) Imaging
Description: MRI of spinal cord and brain

Intervention type: OTHER
Intervention: magnetic resonance (MR) Imaging
Description: MRI of spinal cord and brain

Intervention type: OTHER
Intervention: quantitative muscle force assessment
Description: quantitative assessment of muscle force

Intervention type: OTHER
Intervention: quantitative muscle force assessment
Description: quantitative assessment of muscle force
Study: NCT02130505

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: OGTT
Description: Oral glucose tolerance test (OGTT) with 75 g of oral anhydrous glucose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: OGTT
Description: Oral glucose tolerance test (OGTT) with 75 g of oral anhydrous glucose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: OGTT
Description: Oral glucose tolerance test (OGTT) with 75 g of oral anhydrous glucose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: OGTT
Description: Oral glucose tolerance test (OGTT) with 75 g of oral anhydrous glucose
Study: NCT01088594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone/rosiglitazone/placebo
Description: single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg +single oral dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone/rosiglitazone/placebo
Description: single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg +single oral dose of placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pioglitazone/rosiglitazone/placebo
Description: single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg +single oral dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone/pioglitazone/placebo
Description: single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg + single oral dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone/pioglitazone/placebo
Description: single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg + single oral dose of placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rosiglitazone/pioglitazone/placebo
Description: single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg + single oral dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo/pioglitazone/rosiglitazone
Description: single oral dose of placebo + single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg
Study: NCT01840774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose pain medication (Ketalar) and saline placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low-dose pain medication (Ketalar) and saline placebo
Study: NCT04976842

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OFA
Description: Anesthesiology technique based on Mulier protocol. Before induction, loading dose of dexmedetomidine 0,25mcg/kg (max 20mcg). Induction with dexmedetomidine 0,1mcg/kg, lidocaine 1mg/kg, ketamine 0,1mg/kg plus propofol 2mg/kg plus rocuronium1mg/kg IBW (if required). Maintenance with dexmedetomidine 0,1mcg/kg/h, lidocaine 1mg/kg/h, ketamine 0,1mg/kg/h and propofol infusion adjusted according to bispectral index indication ( BIS maintained 40-60). 15 minutes prior to end of surgery, the dose of drugs is reduced to dexmedetomidine 0,05mcg/kg/h, lidocaine 0,5mg/kg/h, ketamine 0,05mg/kg/h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OBA
Description: Total intravenous anesthesia with propofol for maintenance of anesthesia. Fentanyl 2mcg/kg only at induction and infusion of propofol and remifentanil for maintenance, with doses adjusted according to bispectral index indication ( BIS maintained 40-60).
Study: NCT01088594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo/pioglitazone/rosiglitazone
Description: single oral dose of placebo + single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg
Study: NCT02535741

Intervention type: DEVICE
Group type: OTHER
Intervention: Triathlon CR Total Knee System
Description: Primary total knee replacement
Study: NCT03559712

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative care, Telemental health
Description: Children who are referred to the collaborative tele-mental health care arm, Arm (1), will be given a follow-up appointment with the physician at the same primary care center who have successfully completed the pre-trial didactic program designed by Drs. Albanna and Hamoda. The trained child health physician will conduct assessments, treat and manage the patient. All while having weekly clinical supervision with the specialist.
Study: NCT05165615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin Pump t:slim X2 with Control-IQ technology
Description: Usage of Insulin pump t:slim X2 with Control-IQ technology in previous users of AndroidAPS
Study: NCT01990274

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GeneXpert MTB/RIF assay
Description: Automated nucleic-acid amplification test (fully integrated) test for TB

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Smear microscopy
Description: Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Smear microscopy
Description: Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading
Study: NCT00798369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide
Description: Randomized patients received triamcinolone acetonide 40 mg i.m. once and placebo matching canakinumab s.c. once, on Day 1.
Study: NCT02663635

Intervention type: DEVICE
Group type: OTHER
Intervention: Safe'N'Sound
Study: NCT04173026

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Provider-level intervention
Description: Provider minder is a provider-based scheduling and reminder system for stroke screening in SCD

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Provider-level intervention
Description: Provider minder is a provider-based scheduling and reminder system for stroke screening in SCD

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient-level intervention
Description: 50% of centers are randomized to a single stroke screen coordinator as the point of contact for sickle stroke screen
Study: NCT04475588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itolizumab IV infusion
Description: First dose of 1.6 mg/kg dose iv infusion, , investigator discretion to continue with 1.6 mg/kg dose every 2 weeks or 0.8 mg/kg weekly regimen up to 4 weeks.~BSC: similar to Arm B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best supportive care (BSC)
Description: Best supportive care (BSC) included drugs like antivirals, antibiotics, Hydroxychloroquine, oxygen therapy, LMWH, Steroids, Vitamins and Zinc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best supportive care (BSC)
Description: Best supportive care (BSC) included drugs like antivirals, antibiotics, Hydroxychloroquine, oxygen therapy, LMWH, Steroids, Vitamins and Zinc
Study: NCT01483105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DVD Self-Hypnosis Training Program
Description: The DVD training program contains instructional materials developed by an experienced psychiatrist and psychologist at the Department of Psychiatry at Stanford University School of Medicine. Parents will be instructed to review these materials, watch the DVD, and practice the self-hypnosis exercises every day for a week with their child prior to the upcoming procedure. Parents are encouraged to practice self-hypnosis during their child's VCUG procedure.
Study: NCT03899948

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teacher Anxiety Program for Elementary Students
Description: TAPES consists of three core components: 1) training in evidenced-based anxiety reduction strategies that teachers will implement to identify and assist specific anxious students and classroom-wide strategies helpful to all students, 2) evidenced-based material for teachers to review with parents regarding how to reduce student anxiety at home, thus improving school-home communication and shared goals and 3) training in how to conduct 5 brief (30 minute) teacher-parent-student meetings to teach and practice the TAPES anxiety-reduction strategies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Teacher Anxiety Training
Description: The TAT is a 3-hour professional development training for teachers. Training focuses on recognizing the signs and symptoms related to child anxiety and utilizing classroom-wide strategies to help reduce anxiety in the classroom.
Study: NCT03057938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Florbetaben (FBB)
Description: All participants will receive a single intravenous dose of 300 MBq of FBB followed by PET scan.
Study: NCT03276689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: The patients will take duloxetine for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabaline
Description: The patients will take pregabaline for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The patients will take placebo for 8 weeks.
Study: NCT02431754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alpha1 Blocker
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha1 Blocker
Description: Administered orally
Study: NCT01088594

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo/pioglitazone/rosiglitazone
Description: single oral dose of placebo + single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone/placebo/rosiglitazone
Description: single oral dose of pioglitazone 45mg +single oral dose of placebo + single oral dose of rosiglitazone 8mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone/placebo/rosiglitazone
Description: single oral dose of pioglitazone 45mg +single oral dose of placebo + single oral dose of rosiglitazone 8mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pioglitazone/placebo/rosiglitazone
Description: single oral dose of pioglitazone 45mg +single oral dose of placebo + single oral dose of rosiglitazone 8mg
Study: NCT00588822

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be given as a 375 mg/m\^2 intravenous infusion once weekly for four doses (days 1, 8, 15, and 22).
Study: NCT02276872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral treprostinil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral treprostinil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral treprostinil
Study: NCT01220479

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Exercise training program
Description: Exercise Diabetic and Healthy groups perform a similar training program including two exercise sessions per week, of 90 minutes each, during 9 months (excluding holidays) under supervision by physical education teachers and pediatricians. Sessions comprise various weight-bearing activities: rope skipping, jumping, ball games and gymnastics.~Control groups are relatively inactive.
Study: NCT01979029

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: not preserving the left colic artery
Description: The root of the IMA was exposed and the fatty tissue around the root of the IMA was swept in order to maximize the lymph node retrieval rate. Subsequently, the IMA was ligated 1 cm from the aorta to avoid damaging the nerves.